Burak Emin Gezen, M.D. Internal Medicine - Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 1102 Commerce St, Suite H, Lynchburg, VA 24504 Phone: 434-944-0304 Fax: 434-214-4377 |
Dr. Verna R Sellers, MD Internal Medicine - Geriatric Medicine Medicare: Not Enrolled in Medicare Practice Location: 3300 Rivermont Ave, Lynchburg, VA 24503 Phone: 434-200-4651 |
Christopher Webb, MD Internal Medicine - Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 2215 Landover Pl, Lynchburg, VA 24501 Phone: 434-947-3944 Fax: 866-617-8273 |
News Archive
Pancreatic cancer is one of the deadliest forms of the disease. The American Cancer Society's most recent estimates for 2014 show that over 46,000 people will be diagnosed with pancreatic cancer and more than 39,000 will die from it. Now, research led by Timothy J. Yen, PhD, Professor at Fox Chase Cancer Center, reveals that one reason this deadly form of cancer can be so challenging to treat is because its cells have found a way to sidestep chemotherapy.
Methods currently used around the world for predicting the development of COVID-19 and other pandemics fail to report precisely on the best and worst-case scenarios. Newly developed prediction method for epidemics, published in Nature Physics, solve this problem.
OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer, today announced the online publication in Clinical Cancer Research of preclinical data demonstrating the potent anti-cancer activity of anti-DLL4 (demcizumab) in patient-derived pancreatic tumor models.
The researchers led by Professor Raphael Stoll therefore expect their results to form a basis for future therapeutic strategies to combat cancers caused by HMGA1a.
› Verified 5 days ago